Navigation Links
Edison Expands its Asia-Pac Pharmaceutical Presence with Launch of Coverage of Mesoblast

LONDON, November 27, 2013 /PRNewswire/ --

Edison Investment Research, a leading international investment research firm, announces the initiation of coverage of Mesoblast (MSB: ASX), an Australian-headquartered biotechnology company focused on adult stem therapies.


Mesoblast's pipeline is based on its proprietary mesenchymal precursor cell (MPC) and culture-expanded mesenchymal stem cell (MSC) technologies. Edison's report, Precursor to success, discusses Mesoblast's two technology platforms (MPCs and MSCs) that have to date generated nine clinical candidates (four in Phase III, five in Phase II). The report goes on to analyse the three strategic partnerships with Teva, JCR and Lonza, which underpin the key late-stage programmes including Revascor that could provide US$4bn potential peak sales.

Edison's healthcare team value Mesoblast at A$2.6bn (A$8.07/share) based on a risk-adjusted net present value (rNPV) analysis, which could rise to A$3.2bn (A$10.00/share) if upcoming catalysts are positive.

For the full report see:

About Edison Investment Research

The launch of coverage on Mesoblast is part of a programme of research initiations on biotechnology companies exposed to global market opportunities. Edison provides detailed research coverage on more than 150 pharmaceutical and healthcare companies in Europe, North America, Australia and New Zealand. Its team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. It provides services to more than 400 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. All reports Edison publishes are available to download free of charge from its website

Edison is authorised and regulated by the Financial Services Authority ( Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

About Mesoblast

Mesoblast is developing adult stem cell therapies based on its proprietary MPC and culture-expanded MSC platforms. It has six late-stage clinical trials across four areas: immunologic/inflammatory (Phase III), spine disease (Phase II), cardiovascular (Phase III ready) and cancer (Phase III). The CVS franchise, which is partnered with Teva, could enter Phase III for heart failure in Q413. Worldwide manufacturing of MPCs will be provided by Lonza.

For more information please contact:

Dr Mike Aitkenhead, Edison Investment Research, +44(0)20-3077-5736

SOURCE Edison Investment Research
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Edison expands international bio-pharmaceutical presence with launch of coverage of Onconova Therapeutics
2. Edison Pharmaceuticals Announces Initiation of NIH-Sponsored EPI-743 Clinical Trial with NIH Undiagnosed Diseases Program Patients
3. Edison initiates coverage of Derma Sciences
4. Edison expands North American healthcare sector coverage with initiation of coverage on Alexza Pharmaceuticals
5. Edison Expands North American Healthcare Sector Coverage With Initiation of Coverage on Bellus Health
6. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
7. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
8. Samsung Medison Showcases New Medical Equipment and Technology with Samsung Electronics at RSNA 2012
9. Edison Pharmaceuticals Closes $20M Series F Financing
10. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
11. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
Post Your Comments:
(Date:11/25/2015)... SYDNEY , Nov. 26, 2015  The total global ... nearly 7% over 2015-2016. Latin America ... Asia , (excluding Japan ), is ... continues to face increased healthcare expenditure. In 2013-2014, ... expenditure declined from 43.5% in 2008-2009 to 41.2% in 2013-2014. ...
(Date:11/25/2015)... Nov. 25, 2015 On Tuesday, November ... bellwether trial against Wright Medical Technology, Inc. for ... Conserve metal-on-metal hip implant device, awarded $11 million ... two week trial and three days of deliberations, ... device was defectively designed and unreasonably dangerous, and ...
(Date:11/25/2015)... 25, 2015  Trovagene, Inc. (NASDAQ: TROV ), ... Chief Executive Officer Antonius Schuh, Ph.D., is scheduled to ... Annual Piper Jaffray Healthcare Conference. th ... Palace Hotel in New York ... Mr. Schuh will be available for one-on-one meetings during ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior government and UN ... African Centres of Excellence, and public R&D institutions, civil societies and other partners ... the 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The ...
(Date:11/25/2015)... , ... November 25, 2015 , ... According to an ... robot is being more and more widely heralded as a breakthrough for performing hernia ... method has over traditional laparoscopic surgery is that it can greatly reduce the pain ...
(Date:11/25/2015)... ... 2015 , ... On November 25, 2015, officials of Narconon Arrowhead , ... release of a new cutting edge recovery program that has been 50 years in ... and alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative ...
(Date:11/25/2015)... ... ... On November 23rd 2015 Cozy Products, a division of Bird-X ... Products explains what this means for business moving forward. , The Tri Lite heater ... model: to sell personal heaters that reduce energy consumption, are economical and keep people ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Beddit® has ... Beddit Classic sleep tracking systems. The new app features a more intuitive SleepScoreā„¢ that ... understand how well you slept. The SleepScore is created by a proprietary algorithm. Beddit ...
Breaking Medicine News(10 mins):